Indego® Exoskeleton Receives U.S. Regulatory Clearance for Stroke Treatment

- Indego becomes the broadest available exoskeleton in the U.S. for gait therapy andpersonal use; clearance greatly expands the number of potential patients who can use exoskeletons

CLEVELAND, February 15, 2018 – Parker Hannifin Corporation, the global leader in motionand control technologies, today announced that the U.S. Food and Drug Administration (FDA) has given additional clearance to market and sell the Indego exoskeleton for use in the treatment of individuals with hemiplegia due to stroke. By expanding on its original clearance for individuals with a spinal cord injury, this announcement makes Indego the most broadly available exoskeleton for gait therapy and personal use in the United States.

“We are excited that Indego is now available for a much larger number of patients in theUnited States, enabling stroke patients to have access to this novel gait therapy,” saidAchilleas Dorotheou, head of the human motion and control business unit for Parker.The American Heart Association estimates that 795,000 Americans suffer a stroke everyyear and report that stroke is the leading cause of long-term disability in the country. Assistance with ambulation in a clinical environment may aid in the recovery of gait impairments, which is one of the most desired goals for stroke survivors undergoing
rehabilitation.

The recent FDA clearance came after the completion of a large, multi-site clinical trial involving eight rehabilitation centers in the U.S., where a broad range of stroke patients received gait therapy with Indego and its therapy software suite.

“With the Therapy+ Software Suite, Indego can be used to provide individualized and patient-centric training, which is of critical importance for successful gait therapy sessions with stroke patients,” said Dr. Karen Nolan from the Kessler Foundation, one of the clinicaltrial centers.

About Indego
Indego is a state-of-the-art rehabilitation and assistive technology designed to improve patient mobility and independence while offering clinicians a meaningful therapy tool. Indego has received FDA Clearance and CE Mark, allowing it to be sold commercially in the U.S. and Europe. Indego has also earned a UL Mark which was obtained through extensive testing to certify the high standards of the Indego system design, function, and safety. To learn more about Indego visit www.indego.com.

About Parker Hannifin
Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Learn more at www.parker.com or @parkerhannifin.

###

Media Contacts

Media –
Aidan Gormley, Director, Global Communications and Branding 216/896-3258
aidan.gormley@parker.com